Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 3:45 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 521 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Oral Drug Administration Clear all
Recruiting Not applicable Interventional

Open Label, Controlled, Post Marketing, Registry Study of Ribociclib (Ribo) Treatment Adherence and Patient Reported Outcomes in Participants Using ReX Technology Platform

NCT06344416
View directory record Official record
Conditions
Any Solid Oral Medication
Interventions
Use of ReX to dispense and monitor solid oral medication therapy.
Device
Lead sponsor
Dosentrx Ltd.
Industry
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
4
States / cities
Minneapolis, Minnesota • Austin, Texas • Richmond, Virginia + 1 more
Source: ClinicalTrials.gov public record
Updated Mar 11, 2025 · Synced Jul 22, 2026, 3:45 AM EDT
Completed Phase 1 Interventional

Open-label Study to Evaluate Safety, Tolerability and PK of BHV-0223 in ALS

NCT03520517
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis, ALS, Lou Gehrig Disease, Lou Gehrig's Disease, Lou-Gehrigs Disease, Motor Neuron Disease, Amyotrophic Lateral Sclerosis
Interventions
BHV-0223
Drug
Lead sponsor
Biohaven Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
5
States / cities
Fort Lauderdale, Florida • Lincoln, Nebraska • Charlotte, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2022 · Synced Jul 22, 2026, 3:45 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Pharmacokinetic Study to Assess the Influence of P-glycoprotein Inhibition and Simultaneous CYP3A4 and P-glycoprotein Induction on E7080 Pharmacokinetics Following Single Dose Oral Administration of 24 mg E7080 to Healthy Volunteers

NCT02199392
View directory record Official record
Conditions
P-glycoprotein, Healthy Volunteers
Interventions
Lenvatinib
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
15 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Tacoma, Washington
Source: ClinicalTrials.gov public record
Updated Feb 15, 2015 · Synced Jul 22, 2026, 3:45 AM EDT
Withdrawn Phase 3 Interventional

Study to Evaluate the Safety and Efficacy of Oral Vadadustat in Pediatric Participants With Anemia of Chronic Kidney Disease

NCT05082571
View directory record Official record
Conditions
Anemia of Chronic Kidney Disease
Interventions
vadadustat
Drug
Lead sponsor
Akebia Therapeutics
Industry
Eligibility
4 Months to 16 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Hackensack, New Jersey
Source: ClinicalTrials.gov public record
Updated Sep 30, 2025 · Synced Jul 22, 2026, 3:45 AM EDT
Completed No phase listed Observational Results available

Smart-phone Application to Promote Medication Adherence in Adolescents and Young Adults (AYA) With Cancer

NCT01618344
View directory record Official record
Conditions
Neoplasms
Interventions
Not listed
Lead sponsor
University of Utah
Other
Eligibility
15 Years to 29 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Nov 5, 2017 · Synced Jul 22, 2026, 3:45 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A First-in-Human Study of SBP-9330 in Healthy Subjects

NCT04948827
View directory record Official record
Conditions
Smoking Cessation
Interventions
SBP-9330, Placebo
Drug
Lead sponsor
Camino Pharma, LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Apr 15, 2024 · Synced Jul 22, 2026, 3:45 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Dysport for the Treatment of OMD

NCT01921270
View directory record Official record
Conditions
Oral Dystonia, Tardive Dystonia
Interventions
Low Dose - AbobotulinumtoxinA
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Nov 16, 2017 · Synced Jul 22, 2026, 3:45 AM EDT
Completed Phase 3 Interventional

A Controlled Comparative Trial of Sulfamethoxazole-Trimethoprim Versus Aerosolized Pentamidine for Secondary Prophylaxis of Pneumocystis Carinii Pneumonia in AIDS Patients Receiving Azidothymidine (AZT)

NCT00000727
View directory record Official record
Conditions
Pneumonia, Pneumocystis Carinii, HIV Infections
Interventions
Pentamidine isethionate, Pyrimethamine, Sulfamethoxazole/Trimethoprim, Sulfadoxine/Pyrimethamine, Zidovudine
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
12 Years and older
Enrollment
322 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Ends 1991
U.S. locations
9
States / cities
Los Angeles, California • San Diego, California • San Francisco, California + 6 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2021 · Synced Jul 22, 2026, 3:45 AM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Efficacy and Safety of TAK-906 in Adult Participants With Symptomatic Idiopathic or Diabetic Gastroparesis

NCT03544229
View directory record Official record
Conditions
Diabetic Gastroparesis, Idiopathic Gastroparesis
Interventions
TAK-906 Maleate, Placebo
Drug
Lead sponsor
Millennium Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 85 Years
Enrollment
242 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
67
States / cities
Dothan, Alabama • Tucson, Arizona • Chula Vista, California + 54 more
Source: ClinicalTrials.gov public record
Updated Nov 15, 2022 · Synced Jul 22, 2026, 3:45 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Effects of Food on Oxycodone Pharmacokinetics in Healthy Volunteers

NCT02117583
View directory record Official record
Conditions
Healthy
Interventions
Oxycodone
Drug
Lead sponsor
Pain Therapeutics
Industry
Eligibility
18 Years to 55 Years
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
2
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Apr 3, 2016 · Synced Jul 22, 2026, 3:45 AM EDT
Completed Phase 3 Interventional

Extensive Small Cell Lung Cancer Treatment Using An Investigational Drug Plus Chemotherapy In Chemotherapy-Naive Adults

NCT00043927
View directory record Official record
Conditions
Small Cell Lung Cancer
Interventions
topotecan/cisplatin, etoposide/cisplatin
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
760 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2001
U.S. locations
66
States / cities
Hoover, Alabama • Chula Vista, California • Fountain Valley, California + 57 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2013 · Synced Jul 22, 2026, 3:45 AM EDT
Not yet recruiting No phase listed Observational

A Comparison of a Medication Adherence Platform (FORTISKAP™) vs. Usual Care in Subjects on Oral Medications for the Treatment of Interstitial Lung Disease, Sarcoid and Pulmonary Hypertension

NCT07613216
View directory record Official record
Conditions
Idiopathic Pulmonary Fibrosis (IPF), Sarcoidosis Lung, Pulmonary Hypertension, Usual Interstitial Pneumonia
Interventions
Not listed
Lead sponsor
Cosmos Rx, Inc
Industry
Eligibility
21 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Norfolk, Virginia
Source: ClinicalTrials.gov public record
Updated May 28, 2026 · Synced Jul 22, 2026, 3:45 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study Of Single Doses Of PF-06291826 (Tafamidis) In Japanese And Western Subjects

NCT01369836
View directory record Official record
Conditions
Healthy
Interventions
Tafamidis meglumin, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Sep 12, 2011 · Synced Jul 22, 2026, 3:45 AM EDT
Completed Not applicable Interventional

Freeze-Dried Black Raspberries in Treating Patients With Oral Squamous Cell Cancer Undergoing Surgery

NCT01465776
View directory record Official record
Conditions
Squamous Cell Carcinoma of Mouth
Interventions
laboratory biomarker analysis, preventative dietary intervention
Other
Lead sponsor
Amit Agrawal
Other
Eligibility
18 Years and older
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 5, 2018 · Synced Jul 22, 2026, 3:45 AM EDT
Completed Phase 3 Interventional Results available

Study of Rezafungin Compared to Caspofungin in Subjects With Candidemia and/or Invasive Candidiasis

NCT03667690
View directory record Official record
Conditions
Candidemia, Mycoses, Fungal Infection, Invasive Candidiases
Interventions
Rezafungin for Injection, Caspofungin, Fluconazole, intravenous placebo, oral placebo
Drug
Lead sponsor
Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years and older
Enrollment
199 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
19
States / cities
Birmingham, Alabama • Sacramento, California • Atlanta, Georgia + 16 more
Source: ClinicalTrials.gov public record
Updated Jan 5, 2023 · Synced Jul 22, 2026, 3:45 AM EDT
Completed Phase 2 Interventional Results available

Study to Evaluate the Analgesic Efficacy of 28 Days' Oral Administration of AZD2066 Compared With Placebo in Patients With Painful Diabetic Neuropathy

NCT00857623
View directory record Official record
Conditions
Pain, Diabetic Neuropathy
Interventions
AZD2066, Placebo
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 80 Years
Enrollment
127 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
19
States / cities
Bella Vista, Arkansas • National City, California • Walnut Creek, California + 16 more
Source: ClinicalTrials.gov public record
Updated Nov 11, 2012 · Synced Jul 22, 2026, 3:45 AM EDT
Withdrawn Phase 3 Interventional

A Study of Insulin Peglispro (LY2605541) in Participants With Type 2 Diabetes Mellitus

NCT02106364
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
Insulin Peglispro, Insulin Glargine
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
20 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
10
States / cities
Birmingham, Alabama • Zephyrhills, Florida • Indianapolis, Indiana + 7 more
Source: ClinicalTrials.gov public record
Updated Mar 27, 2016 · Synced Jul 22, 2026, 3:45 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

CoQ10 in Geriatric Bipolar Depression

NCT00720369
View directory record Official record
Conditions
Bipolar Depression
Interventions
CoEnzyme Q10
Drug
Lead sponsor
Mclean Hospital
Other
Eligibility
55 Years to 89 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2010
U.S. locations
1
States / cities
Belmont, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 12, 2014 · Synced Jul 22, 2026, 3:45 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Comparative Pharmacokinetics and Food-Effect Bioavailability of Lubiprostone Sprinkle in Healthy Volunteers

NCT03010631
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Cohort 1: Lubiprostone Capsule, Fasted, Cohort 1: Lubiprostone Sprinkle Formulation, Fasted, Cohort 2: Lubiprostone Sprinkle Formulation, Fed, Cohort 2: Lubiprostone Sprinkle Formulation, Fasted
Drug
Lead sponsor
Sucampo Pharma Americas, LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
49 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Mar 8, 2020 · Synced Jul 22, 2026, 3:45 AM EDT
Withdrawn Phase 3 Interventional

Study to Evaluate Three Times Per Week (TIW) Oral Dosing of Vadadustat for Anemia in Subjects With Dialysis-Dependent Chronic Kidney Disease (DD-CKD)

NCT03242967
View directory record Official record
Conditions
Anemia, Dialysis-Dependent Chronic Kidney Disease
Interventions
Vadadustat, Darbepoetin alfa
Drug
Lead sponsor
Akebia Therapeutics
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
1
States / cities
Northridge, California
Source: ClinicalTrials.gov public record
Updated Nov 4, 2018 · Synced Jul 22, 2026, 3:45 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Bioavailability, Safety, and Pharmacodynamics of Dexlansoprazole Delayed-Release Orally Disintegrating Tablets in Healthy Participants

NCT02064907
View directory record Official record
Conditions
Bioavailability
Interventions
Dexlansoprazole Delayed Release Orally Disintegrating Tablets, Dexlansoprazole Delayed Release Capsules
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 55 Years
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Apr 13, 2015 · Synced Jul 22, 2026, 3:45 AM EDT
Withdrawn Not applicable Interventional

A Mobile Application for Post-op Analgesic Consumption

NCT03197311
View directory record Official record
Conditions
Tooth Extraction Status Nos, Post Operative Pain, Patient Satisfaction, Narcotic Use, Mobile App
Interventions
Mobile app
Other
Lead sponsor
Boston University
Other
Eligibility
18 Years to 40 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 7, 2019 · Synced Jul 22, 2026, 3:45 AM EDT
Completed Phase 2 Interventional

An Evaluation of an Oral Antidiabetic Agent for the Treatment of Type 2 Diabetes

NCT00065312
View directory record Official record
Conditions
Diabetes Mellitus, Non-Insulin-Dependent
Interventions
naveglitazar
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 70 Years
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
42
States / cities
Birmingham, Alabama • Huntsville, Alabama • Peoria, Arizona + 39 more
Source: ClinicalTrials.gov public record
Updated Jul 18, 2006 · Synced Jul 22, 2026, 3:45 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase I, Open-Label, Single-Center Study to Assess the Absorption, Metabolism, and Excretion of [14C]-AZD3293

NCT02126514
View directory record Official record
Conditions
Healthy Volunteers, Mass Balance Study
Interventions
AZD3293
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jun 15, 2014 · Synced Jul 22, 2026, 3:45 AM EDT